The 10-year Jubilee Fernö Symposium 2023


‘Age-related aspects of breast cancer‘




Program Fernö Breast Cancer symposia 2023.


Invited Speakers

Speakers and universities.



Supported by The Swedish Cancer Society.


Welcome to the 10-year Fernö Symposium


28-29 March 2023 


“Age-related aspects of breast cancer” 



Early bird fee until Jan 31st: 2900 SEK

After Jan 31st: 3700 SEK


Registration deadline: March 14th: 


We will make room for 3-4 abstract presentations for PhD students and post docs at each symposium after the keynote lecture. Please note that previously presented abstracts at other meetings also are accepted and may be unrelated to the symposia topics. 



Abstract submission deadline 


Please send your abstract as a word document with Title, Author/-s and Affiliation/-s, containing (max 250 words) the sections: Background/Objective, Material and Methods, Results and Conclusions/Implications to  


The Swedish Translational Research in Breast Cancer (Swe-TRIBE) group is a national group of translational researchers all working within the field of breast cancer. The aim of Swe-TRIBE is to stimulate translational breast cancer research across Sweden with the ultimate aim of paving the way for clinical implementation of research findings. The Swedish Cancer Society financially supports the work of Swe-TRIBE.


Swe-TRIBE organizes an annual translational symposium. We encourage junior and senior researchers to join as participants at the symposium to create a fruitful environment. This is a great opportunity to present your research as well as meeting and interacting with other researchers working within the breast cancer field. This year we again have the honour to welcome a plethora of distinguished speakers. Please see this year’s program below.


Invited Speakers

Lars Holmberg, Uppsala University

Irma Fredriksson, Karolinska Institute

Linda Lindstöm, Karolinska Institute

Marlene Malmström, Lund University

Matteo Lambertini, University of Genova, Italy

Emma Hammarlund, Lund University

Svetlana Bajalica-Lagercrantz, Karolinska Institute